Lixin Zhang-Auberson

Long-term effects of fingolimod in multiple sclerosis

Ludwig Kappos, Paul W O'Connor, Ernst‐Wilhelm Radue, Chris H. Polman et autres

OBJECTIVE: To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day …

ch, ca, de, us, pl, nl (code pays fourni par la source)

SWITCHING THERAPY TO FINGOLIMOD IMPROVES CLINICAL AND MRI OUTCOMES

Eli Silber, L Kappos, EW Radue, Philip Connor et autres

Objectives To evaluate the long-term efficacy outcomes in patients with high-disease-activity switching from placebo to fingolimod, from the FREEDOMS extension study. Methods Patients either continued on the fingolimod dose assigned in the core phase (continuous-group ‘c-group’) or were re-randomised from placebo to …

gb, cl, ca, it, ch, us (code pays fourni par la source)

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

John Dimarco, Paul W O'Connor, Jeffrey Allen Cohen, Anthony T. Reder et autres

us, ca, ch (code pays fourni par la source)

Fingolimod (FTY720) Oral For The Treatment Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Study Design Of The Phase 3 FORCIDP Trial (P6.103)

Hans Peter Hartung, Gen Sobue, Marinos C. Dalakas, Norman Latov et autres

Background CIDP is an acquired immune-mediated inflammatory demyelinating disorder of the peripheral nervous system (PNS). Fingolimod (0.5 mg once daily) is an approved disease-modifying therapy for relapsing multiple sclerosis. In experimental autoimmune neuritis, a T-cell mediated disease model for human inflammatory disease …

de, jp, gr, us, fr, nl, it, ch, gb (code pays fourni par la source)

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

Ludwig Kappos, Jeffrey Allen Cohen, William Collins, Ana de Vera et autres

ch, us (code pays fourni par la source)

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

Jun‐ichi Kira, Yasuto Itoyama, Seiji Kikuchi, Qi Hao et autres

BACKGROUND: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or …

jp, ch (code pays fourni par la source)

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

Marcelo Kremenchutzky, Paul O’Connor, Reinhard Hohlfeld, Lixin Zhang-Auberson et autres

BACKGROUND: Fingolimod is a once-daily, oral sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing multiple sclerosis. OBJECTIVE: This post-hoc analysis of phase 3 FREEDOMS data assessed whether the effects of fingolimod are consistent among subgroups of patients defined by prior …

ca, de, ch, cl (code pays fourni par la source)

Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial

Richard AC Hughes, Marinos C. Dalakas, Norman Latov, Jean Marc Leger et autres

gb, us, gr, nl, it, ch, de (code pays fourni par la source)

Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P01.176)

Hans‐Peter Hartung, Krzysztof W. Selmaj, David Li, Bernhard Hemmer et autres

OBJECTIVE: To evaluate siponimod (BAF312) safety in patients with relapsing–remitting multiple sclerosis during the first 12 months of an extension to the BOLD study.

de, pl, ca, us, es, ch (code pays fourni par la source)

Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial (P07.126)

Ludwig Kappos, Amit Bar‐Or, Bruce Cree, Robert J. Fox et autres

OBJECTIVE: To present the design of a phase 3 study intended to demonstrate the efficacy, safety and tolerability of siponimod as compared with placebo in individuals with secondary progressive multiple sclerosis (SPMS).

ch, ca, us, gb, de, fr (code pays fourni par la source)

Phase 2 BOLD Extension Study Efficacy Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P07.110)

Olaf Stüve, Hans‐Peter Hartung, Mark Steven Freedman, David J. Li et autres

OBJECTIVE: To explore siponimod (BAF312) efficacy in patients with relapsing–remitting multiple sclerosis during the first 12 months of an extension to the BOLD study.

us, de, ca, ch, es, pl (code pays fourni par la source)

Neuregulins

Kim B. Seroogy, Jonathan W. Dickerson, Sarah N. Cassella, Lixin Zhang-Auberson